ADBIOTECH Co.,Ltd. Logo

ADBIOTECH Co.,Ltd.

Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.

179530 | KO

Overview

Corporate Details

ISIN(s):
KR7179530001
LEI:
Country:
South Korea
Address:
강원도 춘천시 동내면 거두단지1길 39, 춘천시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the research, development, manufacturing, and sale of next-generation immune antibodies. The company's core technology is based on Immunoglobulin Y (IgY), producing specific antibodies from eggs as alternatives to conventional vaccines and antibiotics. Its product portfolio serves diverse markets, including livestock, aquaculture, and human health, with commercialized products sold both domestically and internationally. ADBIOTECH is actively expanding its R&D pipeline to include human therapies, such as Helico IgY and Cholesterol IgY, and is entering the global companion animal market with its proprietary VHH (nanobody) technology. The company manages the entire value chain from research to production and sales, positioning itself as a leader in the IgY technology field.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 31.7 KB
2025-09-15 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 133.2 KB
2025-09-15 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 81.3 KB
2025-08-29 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 68.2 KB
2025-08-29 00:00
M&A Activity
[기재정정]경영권변경등에관한계약체결
Korean 17.2 KB
2025-08-22 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 105.4 KB
2025-08-22 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(신주인수권부사채권발행결정)
Korean 102.6 KB
2025-08-22 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 95.8 KB
2025-08-22 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 29.0 KB
2025-08-22 00:00
Pre-Annual General Meeting Information
[기재정정]주주명부폐쇄기간또는기준일설정
Korean 7.6 KB
2025-08-22 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 132.6 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-08-14 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 35.8 KB
2025-08-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 129.8 KB
2025-08-14 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 81.6 KB

Automate Your Workflow. Get a real-time feed of all ADBIOTECH Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ADBIOTECH Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ADBIOTECH Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.